Studies using genetically engineered mouse models indicate that loss of the WT KRAS allele enhances tumorigenesis driven by the mutant one and influences the therapeutic outcome.11–14 This raises the question of whether the WT allele acts as a tumor suppressor and if it is the balance between WT and mutant allele that is crucial for tumorigenesis. Here, KRAS is linked to neoplasm.